The Impact of Tenapanor on Body Composition and Blood Pressure in Peritoneal Dialysis Patients: A Pilot Study
Shun Yoshida, Kengo Asahina, Keiichi Osano, Natsumi Saegusa, Kohei Yamamura, Kie Ohkoshi, Miho Shikata, Toshihisa Ishii, Makiko Konishi, Kazuya Takahashi, Kohei Uchimura, Ayumu NakashimaABSTRACT
Instruction
Tenapanor potentially affects fluid volume and blood pressure. This study explored its effects on these parameters in patients undergoing peritoneal dialysis (PD).
Methods
We conducted a single‐arm, prospective observational study that enrolled 10 patients on PD with hyperphosphatemia who were newly initiated on tenapanor. Body composition was measured using bioelectrical impedance analysis following tenapanor initiation.
Results
At 1 month, total body water, intracellular water, and extracellular water all decreased; however, they returned to baseline by 3 months. Conversely, a reduction in blood pressure was observed at 3 months for both systolic (from 139.2 ± 14.2 to 127.8 ± 9.8 mmHg) and diastolic (from 83.5 ± 12.0 to 76.8 ± 10.0 mmHg) measurements.
Conclusion
Tenapanor administration decreased fluid volume at 1 month in patients undergoing PD. Although the fluid volume returned to baseline by 3 months, a reduction in blood pressure was observed. Long‐term studies are warranted.